Hypoglycaemia is a common and serious complication of diabetes, particularly affecting your patients on insulin therapy. It can have serious acute and long-term impacts.1,2
Watch Prof Rory McCrimmon dive deeper into topics around understanding the mechanisms of hypoglycaemia and strategies to help reduce the risk of hypoglycaemia.
Watch Prof Rory McCrimmon dive deeper into topics around understanding the mechanisms of hypoglycaemia and strategies to help reduce the risk of hypoglycaemia.
References: 1. https://hypo-resolve.eu/project (accessed 15th April 2019). 2. Zhong VW et al. Diabetes Care 2017;40:1651–60.
Toujeo®
(insulin glargine 300 units/mL)PBS Information:
Toujeo SoloStar is listed on the PBS as a long-acting insulin analogue for the treatment of adults with type 1 and type 2 diabetes.
Toujeo SoloStar is listed on the PBS as a long-acting insulin analogue for the treatment of adults with type 1 and type 2 diabetes.
Please review Product Information before prescribing Toujeo.
Further information is available on request from the supplier.
Toujeo® and SoloStar® are registered trademarks of sanofi-aventis australia pty ltd. Sanofi-Aventis Australia PTY LTD trading as Sanofi, ABN 31 008 558 807, Talavera Corporate Centre, Building D, 12–24 Talavera Road, Macquarie Park, NSW 2113.
SAANZ.TJO.19.06.0305. DIB0036. Date of preparation: June 2019.